NCT04387968 (COVIDOR) is a clinical trial of Covid-19 presto test in Coronavirus Infection, sponsored by Raphael Serreau.

Who is sponsoring NCT04387968?

NCT04387968 is sponsored by Raphael Serreau.

What drugs are being tested in NCT04387968?

Interventions in NCT04387968: Covid-19 presto test.

What condition does NCT04387968 study?

NCT04387968 studies Coronavirus Infection.

Is NCT04387968 still recruiting?

NCT04387968 is currently completed. Last updated 5 October 2021.

Last reviewed 2021-10-05 · How we verify

NCT04387968: COVIDOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidemiological Study of the Covid-19 Presto Test - The "COVIDOR" Study

Completed Last updated 5 October 2021

What this trial tests

trial testing Covid-19 presto test in Coronavirus Infection in 3,228 participants. Completed in 4 October 2021.

Timeline

24 August 2020

Primary endpoint
13 July 2021

4 October 2021

Quick facts

Lead sponsor	Raphael Serreau
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,228
Start date	24 August 2020
Primary completion	13 July 2021
Estimated completion	4 October 2021
Sites	2 locations across France

Drugs / interventions tested

Covid-19 presto test

Conditions studied

Coronavirus Infection — all drugs for Coronavirus Infection →

Sponsor

Raphael Serreau

Who can join

Adults 18 to 65, any sex, with Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The "COVIDOR" epidemiological study. Our study would be the first at the community level in Orleans Métropole, aiming to determine the link between a positive IgM level on the serological test and a healthy carrier of covid-19 in agents in contact with the public. It would provide epidemiological surveillance of anti-covid-19 immunity in the community

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

COVID-19 seroprevalence among local authority workers from Orléans Métropole, the Community of Communes of the Terres du Val de Loire, the local public service management centre of the Loiret department and the Region Centre Val de Loire: a prospective epidemiological study.
Hanane G, Amine Z, Roomila N, Prazuck T, et al · · 2023 · PMID 37217267 · DOI 10.1136/bmjopen-2022-066504

Verify or expand the search:

Other recruiting trials for Coronavirus Infection

Currently open trials in the same condition.

NCT04885504 — Post COVID-19 Biorepository · recruiting
NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04387968 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Raphael Serreau
Last refreshed: 5 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04387968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing